Visilizumab
Template:Short description Template:Drugbox Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.[1]
PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] since July 2009[update]Template:Dated maintenance category (articles)Script error: No such module "Check for unknown parameters"..
Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.[6]
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Clinical trial number NCT00938626 for "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma" at ClinicalTrials.gov
- ↑ Script error: No such module "Citation/CS1".
- ↑ Clinical trial number NCT00378508 for "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes" at ClinicalTrials.gov
- ↑ Script error: No such module "Citation/CS1".
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox". Script error: No such module "Navbox".